Can Cord Blood Stem Cells Treat Autism?

Cord Blood Banking

While scientists don’t know exactly what causes autism, they have looked to cord blood stem cells to treat the symptoms because of their regenerative properties.

Here, we look at what researchers know about autism, and why there is reason for both optimism and skepticism in the latest trial research. We also offer some valuable tips on how to evaluate the clinical trials to form your own conclusions.

What Is Autism?

Autism Spectrum Disorder (autism) is a complex condition that affects 1 in 44 children in the U.S., across all racial, ethnic, and socioeconomic groups, according to the Centers for Disease Control [*]. In the last 10 years, autism rates have doubled, a fact some attribute to growing awareness of autism and changes to the condition’s diagnostic criteria [*]. Treatments vary widely [*].

Its symptoms are varied and even today, scientists are still trying to identify its nuances, which typically include social awkwardness, anxiety, repetitive behaviors, and resistance to change.

On the high-functioning end of the spectrum, an individual may have a special capability such as photographic memory or math proficiency. On the low end, there are children with intellectual disabilities and those who don’t talk at all.

Almost a third of children with autism have an intellectual disability and a larger number have issues with motor skills. Boys are 4 times more likely to be diagnosed with autism than girls. According to Johns Hopkins School of Public Health, 1 in 34 boys has autism (2.97%) while only 1 in 145 girls do (.69%). These numbers may be deceptive though, because boys and girls often display different symptoms, with girls more likely to have anxiety versus repetitive behaviors common in boys. It’s possible that some girls with autism are being misdiagnosed with anxiety or depression instead of autism.

The word autism was first used to describe the disorder in the 1920s by a Ukranian-born Jewish female psychologist named Grunya Sukhareva, writing 20 years before Hans Asperger and Leo Kanner, who until recently were credited with the discovery of autism [*].

Almost a century later, researchers still don’t know exactly what causes autism and thus have no means of preventing it, reducing its severity or its risk of occurring. This is the problem at the crux of treating autism in a targeted manner.

What Causes Autism? The Latest Research

Scientists recognize genetics has a role in autism, but the research to fully understand this may be years, or even decades, away. What scientists do know is that genetic mutations called copy-number variations, in which large chunks of an essential and specific genome get deleted or duplicated, are present in a substantial number of autistic individuals [*].

In at least 30% of autism cases, these de novo mutations (meaning they weren’t present in either parent) play out differently in boys than girls; It takes a larger hit to the gene to make a girl autistic. This led genetic scientists studying autism to think that the mothers passed a strong autism-causing variant to their offspring, but further research debunked that theory.

The opposite proved true: In families with more than one sibling affected by autism, the siblings shared more of their father’s genome [*].

Immune dysregulation is another promising area of research into the cause of autism. Researchers have determined that the mother’s immune system may be triggered during pregnancy to impair fetal development. For instance, if she suffers from a high fever during pregnancy in the second trimester, the chance of the baby developing autism increases by 40% [*].

It’s also possible that a maternal-fetal conflict could cause autism, where the mother’s immune system reacts to an antigen (protein) from the father’s genome which it then attacks in the fetus [*].

Other causes noted in recent research include synaptic pathology, hormone imbalances, and exposure to neurotoxins [*]. Researchers have also suggested autoimmune disorders among the parents increase the risk of autism in offspring [*].

A healthy pregnancy is the first line of defense against autism, but it is by no means a guarantee.

What Is Cord Blood?

Cord blood is gathered from a newborn’s umbilical cord after birth. It’s a precious resource of stem cells — the building blocks of our blood and immune systems. Once considered medical waste, the umbilical cord contains both hematopoietic stem cells (in the cord blood) and mesenchymal stem cells (in the cord tissue). These stem cells have different properties.

There are more than 80 FDA-approved cord blood stem cell treatments for diseases such as leukemia, sickle cell anemia, and other heritable blood disorders. Stem cells from cord blood offer several advantages over stem cells from bone marrow: they’re more readily available, easier to match, cord blood collection is non-invasive, carry a lower risk of infection, and present less risk of graft-versus-host-disease (GVHD).

The ability of stem cells to develop into various cell types, and the ease with which they can be expanded in culture, has led to a great deal of interest in their use in therapies targeting a wide range of diseases, including autism.

How Can Cord Blood Help Autism?

Cord blood stem cells exert a paracrine effect, meaning that these cells can stimulate the patient’s own cells to repair diseased tissue, reduce inflammation, promote the growth of blood vessels (angiogenesis) and stimulate the proliferation and migration of neural stem cells without contributing to such tissue directly [*].

Researchers don’t know exactly what combination of genetics, epigenetics, and immunological components cause autism, so the clinical trials vary based on what hypothesis the researchers proceeded from — among many other factors discussed in a moment.

During the early phase of brain development, there is a close relationship between the immune and nervous systems, leading researchers to hypothesize that there is a link between neuroinflammation, microglial activation, and immune dysregulation in autism patients [*][*].

Recent reports suggest that stem cell transplantation using MSCs may improve neurological conditions resulting from stroke, amyotrophic lateral sclerosis, Alzheimer’s disease, spinal cord injury, or Parkinson’s disease [*].

Clinical Trials for Cord Blood and Autism

Chinese Clinical Trial – 2013

This study was the first to present a safety and efficacy analysis of using allogeneic human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) for autism in addition to conventional behavioral therapy.

This non-randomized, open-label, single center phase I/II trial studied 37 children (age 3-12, almost all male) who were given intravenous infusion as well as multiple injections of the cord blood preparations, which were not derived from the children in the study but rather, donated and expanded by Shenzhen Beike Cell Engineering Research Institute (SBCERI).

The study divided the participants into three groups: the Control group received only conventional behavioral therapies; the CBMNC group received CBMNCs and behavioral therapies; and the Combination group received a combination of CBMNCs and UCMSCs and behavioral therapies.

The researchers deemed the treatments safe and effective, although some participants developed low-grade fever that resolved on its own. Both the CBMNC and Combination groups saw significant behavioral improvements compared with the Control group, using the CARS and ABC assessments. The Combination group saw the most improvement overall in visual, emotional, and intellectual responses, body use, adaption to change, fear or nervousness, nonverbal communication, and activity level, as well as in lethargy/social withdrawal, stereotypic behavior, hyperactivity, and inappropriate speech.

Along with the encouraging results, the authors note the limitations of this proof-of-concept study. First, the subjects were not randomized or stratified based on disease severity or another demographic variable. The small number of subjects, and the fact they were only followed for 24 weeks, may introduce bias as to the safety and efficacy measures. This was an open label trial, meaning that neither evaluators nor subjects were blinded, which may have introduced bias as to the behavioral measurements. Finally, the exact mode of action was not known or clarified in this study. In other words, they don’t know exactly how or why they got the results they did. [*]

Duke Autism Center Phase I Trial – 2017

Much has been made on the various cord blood blogs about the research from Dr. Joanne Kurtzberg and her team at the Duke Autism Center, who have been studying cord blood treatment for autism.

The Center’s open-label, Phase 1 clinical trial found some behavioral improvements in a small number of autistic children treated with a single infusion of their own cord blood, leading the authors to conclude that such treatment is “safe and feasible” [*]. But the authors note this caveat:

“While these results provide some promise for future work with cord blood-derived therapies in autism, it is important to note the limitations of this study. As an uncontrolled open-label study, it is not possible to determine whether the observed behavioral changes were due to the treatment or reflect the natural course of development during the preschool period.”

Duke Autism Center White Matter Study – 2019

In a second study in 2019 from these researchers and this same group of 25 autistic children ages 2-6, the authors sought to understand whether the improvements they observed in social function, communication abilities and reduced clinical symptoms in the first trial were associated with changes to brain structural connectivity: white matter.

White matter tracts are the synapses in the brain that transfer information. The researchers of this study hypothesized that damage to these tracts may be the cause of the abnormal behaviors associated with autism.

The authors in this study believe their results support a finding that the improvements they saw in the earlier study were associated with increased structural connectivity in brain networks supporting social, communication, and language abilities [*].

However, a 2020 study on white matter in both adults and children with autism found that the white matter tracts that are the most impacted in autism may not be (at least directly) responsible for the behavioral deficits in autism [*].

Duke Autism Center Phase II Trial – 2020

In 2020, the Duke Autism Center researchers completed a Phase II study that was double-blind, randomized, and placebo-controlled. It did not show significant benefits to the study participants.

When they removed children with intellectual disabilities from the analysis, they reported some improvements in communication, eye tracking, and EEG measurements [*].

The authors have recruited for another clinical trial.

The Trouble With Evaluating Clinical Trials for Autism

What makes these trials and others so hard to evaluate include:

  • The range of therapeutic targets — e.g., immune dysregulation, synaptic pathology, etc. — because no one knows the precise cause of autism.
  • The small audience for these trials — limited to mostly white children who have cord blood stored privately or publicly for autologous infusion treatments.
  • Patient stratification — as seen in the Duke study that separated the children with intellectual disabilities from the group to demonstrate results for a subset.
  • The method of evaluation — there seem to be several autism scales and evaluation criteria in use to evaluate behavioral changes.
  • The lack of a baseline showing what might be natural improvement with advancing age in autistic children.
  • The administration via IV into the bloodstream — how do these cells get into the brain? Is one infusion enough? Is it the best method? Is it the only method?

To better evaluate these studies (and make for less ambiguous future studies [*]), we need to know:

  • What specific dysfunction or therapeutic target is being proposed?
  • What evidence is there that this dysfunction is expressed in a particular group of autism patients?
  • What is the mode of action by which the cell therapy seeks to rebalance that dysfunction?
  • If the dysfunction is reversed, is there evidence it will bring about an improvement in the core symptoms of autism?
  • And finally, is there any evidence that once autism manifests it is reversible [*]?

Conclusion

If you’re at a loss for what conclusion to draw here, you’re not alone. There are those who find the research done to date on cord blood for autism very promising [*] and are optimistic a cord blood stem cell treatment might improve the symptoms of autism. There are also those who greet the Duke studies to treat autism with skepticism [*].

And there are those in the scientific community who find the results ambiguous or inconclusive because of the ways the studies were conducted and the limited number of participants [*].

The biggest hurdle to effective medical treatment, not to mention prevention, is our lack of understanding as to what causes autism. Stem cell treatments targeting immune dysregulation or white matter in autism patients have shown promise, but there is no firm evidence that autism can be reversed by cord blood stem cell transplant (or any other therapy for that matter). At least, not yet.

For a disorder that is becoming ever more prevalent for reasons we don’t fully understand, there is hope that each successive trial will bring us closer to a stem cell treatment that will improve the symptoms, if not eventually find a cure.

80 Good Reasons to Save Cord Blood

With more than 80 FDA-approved treatments using cord blood stem cells for a wide range of heritable diseases and 5,200+ clinical trials initiated, there are a lot of compelling reasons to save your baby’s cord blood and cord tissue with an honest and ethical cord blood bank such as MiracleCord.

To learn more about what cord blood can do for your child and your family right now, download MiracleCord’s Info Kit.

Here's what you need to know now.

DISCLAIMER: THE INFORMATION ON THIS WEBSITE IS NOT INTENDED TO BE USED AS MEDICAL ADVICE. The materials and information contained on the MiracleCord website is provided for educational and informational purposes only, and is not intended to, and does not constitute, medical or other health advice or diagnosis, and should not be used as such. You should not use this information to diagnose or treat a health problem or disease. If you are seeking personal medical advice, you should consult with a licensed physician. Always consult with a qualified health care provider regarding a medical condition.

Mark Locascio is the Founder and CEO of MiracleCord. Recognized in 2022 as one of Illinois’ top 32 biotech CEOs, he has spent nearly two decades making cord blood banking accessible to families nationwide.

Related Posts

Client Agreement

MiracleCord, Inc. (“MiracleCord”) is a provider of services for the collecting, testing, processing, cryopreserving and storing of cells collected from a newborn’s umbilical cord blood (“Cord Blood”) as well as certain umbilical cord tissue (“Cord Tissue”), (individually a “Neonatal Specimen” or collectively “Neonatal Specimens”). This Client Agreement (“Agreement”) explains MiracleCord’s obligations to you (“Client”) and your agreements with MiracleCord, and to ensure, where applicable, that where there is a birth mother other than Client (e.g., a surrogate, gestational carrier or birth mother placing a baby for adoption – referred to herein as a “Birth Mother”) consents to the terms of this Agreement and the obligations that may then reside with the Birth Mother per the Agreement.

MiracleCord’s Obligations
1. MiracleCord shall provide to the Client (or to the Birth Mother, when applicable) a collection kit for the Client or Birth Mother to bring to the hospital or other birth location for the collection of the Client’s newborn baby’s Cord Blood and/or Cord Tissue, and a maternal blood sample (collectively “Specimens”). MiracleCord shall include with the collection kit reasonable directions for the attending medical professional for the use of the kit and the collection of the Neonatal Specimens.
2. As soon as possible after the Specimens have been collected, the Client (or the Birth Mother, when applicable) will contact MiracleCord’s medical courier partner (“Courier”) to request pick up. The Courier will pick up the Specimens at the birth location and deliver them to MiracleCord’s laboratory partner (“Lab”).
3. Upon arrival at the Lab certain tests will be conducted on the Specimens.
4. The Neonatal Specimens will be uniquely identified, stored, and maintained at a cryogenic storage facility, and shall remain in cryopreserved storage for the full period of the Agreement between MiracleCord and Client or until the Agreement is terminated as provided for in this Agreement.
5. MiracleCord reserves the right to transfer the Neonatal Specimens, at its cost, during the term of this Agreement.
6. Upon receipt by MiracleCord of a written request from the Client, MiracleCord shall arrange for some or all of the Neonatal Specimens (as requested by the Client) to be transported directly to a physician appropriately qualified to perform a transplant or medical procedure (“Physician”), or to a medical care facility, to be used in a medical procedure as determined by Client and Client’s physician, subject to FDA guidelines. Except as otherwise provided in this Agreement, MiracleCord shall not transport the Neonatal Specimens from the storage facility to any party, including Client, other than to a physician or medical care facility for a medical procedure. The initial transportation within the United States of the Neonatal Specimen(s) as provided herein shall be at MiracleCord’s expense. A subsequent transportation of the Neonatal Specimen(s) within the United States, or the transportation of the Neonatal Specimen(s) outside of the United States shall be at Client’s expense.
7. Upon termination of this Agreement for storage of the Neonatal Specimens between MiracleCord and the Client, MiracleCord will transport, at Client’s cost, the Neonatal Specimens to a physician, medical care facility or appropriately accredited or licensed cryopreservation laboratory/storage facility, as directed by Client and subject to all applicable laws and regulations. Such direction shall be in the form of a document provided to Client that shall be executed, notarized and returned to MiracleCord. Alternatively, at Client’s direction (in accordance with the preceding), or if no direction is provided by Client within sixty (60) days after termination, MiracleCord or the Lab will dispose of the Specimens in an appropriate manner, including but not limited to transfer to a research facility.

Client’s Obligations
1. The Client will carefully read and execute this Agreement and ensure the Client (and Birth Mother, where applicable) has completed the Health History Profile and the “Parent” section of the Collection Worksheet provided by MiracleCord. The Client is encouraged to have the documentation related to the collection, testing, processing and storage of the Specimens reviewed by Client’s counsel and medical professional of Client’s choosing.
2. As provided for in this Agreement and for avoidance of any doubt, if the Client executing this Agreement is not the Birth Mother of the child whose Neonatal Specimens are being collected, the Client will obtain the written consent of the Birth Mother to all of the applicable terms and conditions in this Agreement by having her sign this Agreement.
3. The Client will select the medical facility and medical professional that will conduct the collection of the Neonatal Specimens. The Client acknowledges the selection of the medical facility and the medical professional is solely the responsibility of the Client and that MiracleCord does not select or otherwise determine who shall perform these services.
4. Client agrees to notify the medical professional and the medical facility staff of the desire to collect the baby’s Cord Blood (and Cord Tissue if applicable).
5. As soon as possible after collection of the Specimens, the Client or Birth Mother will call the Courier to request pick up of the Specimens for delivery to the Lab.
6. If the checkbox in the top section of the “Parent” section on the Collection Worksheet is not checked and the baby’s cord tissue sample arrives at the Lab, it will be processed and stored, and the Client will be billed for the applicable cord tissue fees.
7. The Client will make all payments in a timely manner.

Fees and Plans
1. At the time of initial enrollment of the Client to receive MiracleCord’s services, the Client will pay a non-refundable deposit of $200.00 (in the event of multiple births, the deposit will be $200.00 per baby). Upon collection of the Specimens, Client shall be obligated for the payment of the balance of the fees for the plan as selected by the Client. By accepting this Agreement, if the Client elects a financing arrangement for the fees, Client hereby accepts the Payment Plan Disclosure provided to Client via email, or if not provided by email, then on the MiracleCord website. Other terms and conditions may apply. Acceptance of the Client Agreement, including all of the terms and conditions herein, shall occur upon either (i) execution of this Agreement or (ii) payment of the non-refundable $200 deposit.
2. Upon accepting this Agreement, the Client will select one of the storage and payment plans that is on MiracleCord’s website for online enrollment. Storage plan options include an annual plan and long-term plan(s).
3. The annual plans include: (a) a separate fee for the initial service, which includes testing and processing of the Specimens, the transport of Specimens by the Courier to the Lab, and the collection kit for the Specimens, and (b) the storage fee for the first twelve months. Thereafter, the Client will be invoiced for additional annual storage fees. Annual storage fees will be charged automatically to the credit/debit card on file approximately fourteen (14) days before your baby’s birthday, unless you have chosen a long-term storage plan. Annual storage plan fees may be adjusted from time to time.
4. The long-term plans include: (a) a separate fee for the initial service, which includes testing and processing of the Specimens, the transport of Specimens by the Courier to the Lab, and the collection kit for the Specimens, and (b) the applicable storage fee for the period set forth in the specific long-term plan selected by the Client.
5. The Client will be charged a late fee equal to 10% of the amount due if any required fee is not paid when due. Additionally, any amount not paid within thirty (30) days of the date due shall accrue interest at the rate of 1.5% per month until paid.
6. As set forth above, there is no MiracleCord fee for an initial transfer of the Neonatal Specimen(s) that is retrieved by the Client to be used in an engrafting or transplant procedure within the United States. MiracleCord shall be responsible for any shipping or courier costs for an initial transfer of the Neonatal Specimen(s) for use in such medical procedure within the United States. The Client shall be responsible for any shipping or courier costs for any subsequent transfer of Neonatal Specimen(s), or for any transfer to any location outside of the United States. The fee to transfer the Neonatal Specimen(s) that is retrieved by the Client for any reason other than an engrafting or transplant procedure will be made available to Client by MiracleCord by contacting MiracleCord prior to requesting retrieval of the Neonatal Specimens.

Limitations of the Program
1. MiracleCord shall have no liability in the event of:
a. Failure of the medical professional to correctly collect, label or assemble the Specimens inside the collection kit;
b. Failure of the medical professional to attend to any medical issue that arises during the delivery of the newborn, even if such failure was due to such medical professional’s attention to collecting the Specimens;
c. Failure of the Courier to deliver the Specimens, due to loss or destruction of the Specimens while in the Courier’s possession;
d. Any contamination of the Specimens at the time of collection and up until the Specimens are delivered to the laboratory for further processing and testing;
e. Any event that harms or contaminates the Specimens that was beyond the reasonable control of MiracleCord, such as, fire, explosions, power outages, storms, floods, terrorism, wars, labor disputes, governmental action, imposition of statutes, laws or regulations that materially alter the program for collection, processing, testing and storage of the Specimens;
f. Any failure of an engrafting procedure or transplant of the Neonatal Specimens, except as provided in MiracleCord’s Quality Guarantee with respect to Cord Blood.
2. MiracleCord’s liability to the Client for any claims, loss, harm, damages, expenses, costs (including attorneys’ fees) shall be limited to a return of the fees paid by Client for MiracleCord’s services under this Agreement.
3. In the unlikely event a Neonatal Specimen is reasonably determined to be inappropriate for the program, MiracleCord will return to Client any storage fees paid by Client in advance, whether under any annual or long-term plan.
4. MiracleCord shall have no liability for, and Client hereby releases and discharges MiracleCord from any obligations with respect to, any disclosure of information in accordance with the Privacy Policy that is attached to this Agreement and/or provided on MiracleCord’s website.

Quality Guarantee
As a MiracleCord client, the viability of your baby’s umbilical cord blood stem cells is guaranteed by MiracleCord with respect to the initial stem cell transplant procedure. If, in an initial stem cell transplant procedure, your child’s Cord Blood stem cells fail to engraft, MiracleCord will pay up to one hundred thousand dollars ($100,000) toward the cost of procurement of an alternative stem cell source, if medically indicated. Cord Tissue is specifically excluded from the terms of this quality guarantee.
1. Definition of Engraftment – Stem cell engraftment is defined as three consecutive days in which the patient’s absolute neutrophil count is at least 500 per microliter, with the first of the three measurements occurring within 100 days of transplantation.
2. Quality Guarantee Medical Requirements:
a. The Cord Blood must have been collected with a MiracleCord collection kit and processed and cryogenically stored by the Lab, and cannot subsequently have been transferred to a storage facility other than a MiracleCord Lab;
b. The results of the testing by the Lab of the Cord Blood and maternal blood must show no evidence of infection or contamination;
c. The cells must be used in a stem cell transplant for hematopoietic reconstitution either by the donor (autologous) or by the donor’s biological parents or biological siblings;
d. The donor cells must be at least a 4 out of 6 HLA match to the recipient;
e. The Cord Blood unit must contain at least 2 x 107 total nucleated cells (TNC) per kilogram weight of recipient;
f. The Cord Blood unit must contain at least 1 x 105 CD34+ cells per kilogram weight of recipient;
g. The transplant facility must use a validated cord blood thawing procedure, and the cord blood stem cells must be administered immediately upon thawing;
h. The stem cells must be administered to the transplant recipient by a transplant physician, in a medical facility qualified by an Institutional Review Board (IRB) for stem cell transplantation;
i. The cells must not be subjected to manipulation, cell expansion, positive or negative cell selection, or gene therapy;
j. The patient must be given sufficient time (post-transplant) for engraftment to occur;
k. The stem cells must not be used in combination with supplemental stem cell sources, including, but not limited to, additional cord blood, peripheral blood, or bone marrow;
l. The stem cells must not be used in experimental procedures, including, but not limited to, mini-transplants, or other types of extensive and/or experimental laboratory cultures;
m. The stem cells and/or transplant recipient must not be subjected to an investigational drug within 100 days of transplantation.
3. Quality Guarantee Documentation Requirements:
a. Signed statement from the transplant physician attesting that engraftment did not occur;
b. Medical records documenting proof of non-engraftment;
c. Proof that all third-party payers responsible for payment of any fees associated with the collection, storage, or transplant of the Cord Blood have been notified of the existence of MiracleCord’s Quality Guarantee and the amount to be paid.
4. This Quality Guarantee is not available to:
a. Clients that reside in areas where this guarantee is prohibited by law, or in the event the transplant procedure is performed outside of the United States;
b. Clients whose cord blood banking fees or transplant fees are paid in full or in part by Medicare or Medicaid;
c. Clients whose cord blood banking fees (i) are paid in part or whole by third-party payers in Massachusetts and Michigan or (ii) have been waived or forgiven, in whole or in part, by MiracleCord prior to the request by the Client for transplant of the stem cells;
d. Clients who have an unpaid balance due to MiracleCord for services rendered;
e. Clients enrolled in MiracleCord’s Select Transplant Program.
f. Clients who have directed a transfer of the Neonatal Specimens to any location other than to a Physician or medical care facility for use in a transplant or medical procedure.
5. Your baby’s Cord Blood is not guaranteed to be a match for a family member, and an umbilical cord blood transplant may not provide the best course of treatment for any particular disease. Ultimately, the use of your child’s cord blood stem cells will depend on the physician’s determination of disease type and the HLA matching for donor and recipient.

Informed Consent
1. To confirm that the Client (a) understands the services to be provided by MiracleCord, and (b) has been informed of the processes and procedures that will be performed by MiracleCord or the Lab, the following provisions regarding the Client’s informed consent for such engagement and receipt of services is incorporated into this Agreement. The term “I”, as used in this informed consent provision, is a reference to the Client and, where different from the Client, the Birth Mother:

I acknowledge that I have decided and consented to have my baby’s Cord Blood and/or Cord Tissue (as applicable) collected after the birth of my baby and to have such Neonatal Specimens tested, processed, cryopreserved and stored. I also agree to provide samples of my own blood for testing. Although infrequent, I understand that at the time of childbirth complications may occur and attending to my health or the health of my newborn is the priority; therefore, it may not be possible to collect my baby’s Neonatal Specimens.

I acknowledge that it is my decision to select the medical professional that will attend to the birth of my baby and conduct related medical procedures, including the collection of my baby’s Neonatal Specimens. I understand that MiracleCord may contact the medical professional for the purposes of discussing MiracleCord’s services, and in certain cases, such medical professional may receive payment from MiracleCord for performing services related to the collection of my Specimens. In order to ensure and enhance the communications for my benefit between the hospital, medical professional and MiracleCord, I hereby authorize the hospital and medical professional to disclose my protected health information related to the collection of my Specimens with MiracleCord. MiracleCord may provide the hospital and medical professional with a copy of this authorization. I understand that I am entitled to be provided a copy of any disclosed information and that this authorization can be revoked at any time. I understand that MiracleCord will not use my protected health information for marketing or promotional purposes.

I understand that the Lab will perform tests on the Cord Blood, including cell viability, total nucleated cell count, CD34+, bacteria and fungus to determine the nature and quality of the Cord Blood, and the Lab will perform tests on the Cord Tissue (if collected), including cell viability and sterility, to determine the nature and quality of the Cord Tissue, and that my blood will be tested for certain infectious diseases including human immunodeficiency virus (HIV), hepatitis B and hepatitis C viruses, human T-lymphotrophic virus (HTLV), cytomegalovirus (CMV), and syphilis. I understand that if applicable law, regulations, certification requirements or industry standards are modified or amended, then alternative, additional or substitute tests may be performed. I acknowledge and consent to MiracleCord and the Lab making such reports of the results of these tests as required by applicable law.

I understand that MiracleCord may elect not to retain the collected Neonatal Specimens if, in MiracleCord’s reasonable judgment such Neonatal Specimen is not appropriate for storage. Such reasons may include, but are not limited to, if there is any condition that may affect the viability of the future use of such Neonatal Specimen. The final decision as to whether such Neonatal Specimen is appropriate for storage shall be that of MiracleCord and the Lab. I understand that I will be notified in writing of a decision that such Neonatal Specimen is not appropriate for either testing or storage, and such a determination shall result in the termination of any further obligations of either party under this Agreement.

I understand that there are potential benefits of Cord Blood and Cord Tissue for use in the treatment of certain diseases and conditions. I also understand that the limits of the longevity of storing Neonatal Specimens are not completely known. I acknowledge that it is not possible to know if transplanting Cord Blood or Cord Tissue stem cells will be effective in the treatment of any particular diseases or conditions. I understand that the Neonatal Specimens are a perfect match for my baby, and have been informed that, unless and until further testing is completed, it is not possible to know whether the Neonatal Specimens will be a match for any other particular individual. I understand that the collection of Specimens, and transplantation of Neonatal Specimens are medical procedures, and that there are inherent risks in any medical procedure. I acknowledge that MiracleCord does not and will not, perform, advise, or participate in any way in such medical procedures and will not have any liability for such medical procedures, and I release and discharge MiracleCord from any such liabilities.

Miscellaneous
1. Confidentiality – MiracleCord acknowledges the confidential nature of the Client’s information provided to MiracleCord (and the information about the Client’s child) and will use its reasonable best efforts to maintain the confidentiality of such information, except as may be required by applicable law. The Client agrees to the release of information by MiracleCord to any medical facility, hospital, laboratory or medical professional providing services to the Client that are related to the Specimens, including the provision of any engrafting or transplant procedures.
2. Termination by Client – This Agreement may be terminated by the Client (a) at any time prior to collection of the Specimens, or (b) after giving MiracleCord at least sixty (60) days prior written notice at any time after storage of the Neonatal Specimens. All fees paid through the date of termination are non-refundable.
3. Termination by MiracleCord – This Agreement may be terminated by MiracleCord (a) if MiracleCord has determined any such Neonatal Specimen is not appropriate for storage, in which case MiracleCord will return to Client any storage fees paid by Client in advance for such Neonatal Specimen, whether under any annual or long-term plan, (b) if Client does not timely pay any fee when due, or (c) at any time after giving Client at least sixty (60) days prior written notice of such termination, in which case MiracleCord will return to Client a pro rata portion of any storage fees paid in advance under any annual or long-term plan.
4. Upon termination of this Agreement by Client in accordance with Section 2 above, or by MiracleCord in accordance with Sections 3(a) or 3(c) above, and after storage has commenced, Client may request to retrieve the Neonatal Specimen and shall pay the applicable retrieval fee at such time. If either (a) pursuant to the preceding sentence, Client does not request retrieval of the Neonatal Specimen or (b) MiracleCord has terminated the Agreement in accordance with Section 3(b) above, MiracleCord, without liability, shall be free to use or dispose of such Neonatal Specimen in an appropriate manner, including but not limited to transfer to a public cord blood or tissue bank or to a research facility. Client hereby releases and discharges MiracleCord from any and all claims, liabilities, costs or actions that may arise out of or result from MiracleCord’s activity or handling of the Specimens after termination. In addition to the foregoing, MiracleCord shall be entitled to recover from Client all costs and fees (including reasonable attorney’s fees) incurred in any action to collect any amounts due from Client under this Agreement.
5. Consent to Communications – Client understands and agrees that MiracleCord and Client communications may occur in several different ways and means of communication. Client agrees that MiracleCord may communicate with Client by means of any of email, text messaging, telephone, or written communication. Client has the right to opt out of such communications by using that means of communication you wish to stop at any time: (i) an email to MiracleCord at [email protected]; (ii) a text “STOP” in response to a MiracleCord text; (iii) a call to MiracleCord customer services at 1-888-743-2673 or (iv) by letter to MiracleCord at 875 N Michigan Ave, Ste 3100, Chicago, IL 60611.
6. Notices – Any notice either required or permitted under this Agreement may be given (a) personally to the other party, (b) by private delivery services (e.g., Federal Express or UPS) with a return receipt requested, or (c) by United States registered or certified mail return receipt requested. Notice shall be sent to the other party at their last known address.
7. Dispute Resolution – In the event of any dispute between the Client (or Birth Mother where applicable) and MiracleCord with respect to this Agreement or related in any way to the collection, testing, processing and storage of the Specimens, or a dispute over any payments or fees, such dispute will be submitted to binding arbitration under the rules of the American Arbitration Association (the “AAA Rules”). The arbitration will be held in Chicago, Illinois before a single arbitrator. The fees of the arbitrator will be shared equally by the parties. Other than such arbitrator fees, the prevailing party in such arbitration, as determined by the arbitrator will be entitled to recover its costs and expenses of the arbitration. The arbitrator will issue a written opinion of his/her decision, and such decision will be binding, final and enforceable in any court of competent jurisdiction.
8. Governing Law – This Agreement and the relationship between the Client, the Birth Mother and MiracleCord shall be governed by and interpreted in accordance with the laws of the State of Illinois without regard to its choice of laws rules.
9. Assignment – Upon the attainment of the age of majority by the child from whom the Neonatal Specimens were collected (the age of majority as determined in the state of the domicile of the child, but in no event earlier than the age of majority in the State of Illinois), the Agreement between the Client and MiracleCord shall be assigned to such child who shall then be the Client hereunder. Additionally, if different from the initial Client, this Agreement shall be assigned to any guardian of the child from whom the Neonatal Specimens were collected. MiracleCord may assign its rights and obligations under this Agreement (i) to any acquirer of the majority of the stock of MiracleCord or substantially all of the assets of MiracleCord or (ii) in the unlikely event that, for any reason, MiracleCord ceases to be an ongoing concern, to ensure the uninterrupted provision of services, MiracleCord may assign its rights and obligations under this Agreement to the Lab. Except for the foregoing circumstances, neither the Client nor MiracleCord shall assign its rights and obligations under this Agreement without the prior written consent of the other party. All of the terms and conditions shall be binding on any successor or assign of a party.
10. Waiver – No waiver by any party with respect to any breach or default or of any right or remedy, and no course of dealing, shall be deemed to constitute a continuing waiver of any other breach or default or of any other right or remedy, unless such waiver is expressed in writing signed by the party to be bound by such waiver. Failure of a party to exercise any right, under this Agreement or at law or in equity, shall not be deemed a waiver of such right or rights in the future.
11. Severability – If any of these terms and conditions are held to be invalid or unenforceable, such invalidity or unenforceability will not affect the other terms and conditions, which will remain in full force and effect.
12. Entire Agreement – This Agreement, and the attachments to this Agreement, represent the entire agreement between the Client and MiracleCord and supersede any oral or written prior agreements, representations, or understandings.

The Client (and the Birth Mother, if different than the Client, and solely with regard to those provisions of this Agreement that are applicable to the Birth Mother) has indicated acceptance of this Agreement as of the date set forth below.

Client                                                                Birth Mother

__________________________________             __________________________________
Printed Name                                                    Printed Name

__________________________________             __________________________________
Signature                                     Date              Signature                                     Date

CLIENT RIGHTS
Medical care for the birth mother and baby is of the highest priority to MiracleCord. If the medical condition of the mother or baby becomes a concern, the collection process should be withdrawn. Under no circumstances should the collection process be completed if any medical care would be sacrificed to the mother or baby. The Client’s healthcare professional is responsible for identifying any circumstances that would put the mother or baby at risk. The Client also has the right to deny consent of the collection at any time without affecting access to medical care. Also, the Client has the right to have any and all questions answered concerning any part of the process, completion of the forms, testing for infectious diseases, and storage (this list is not all-inclusive).

PRIVACY POLICY
MiracleCord takes seriously its obligation to keep all personal and health information strictly confidential and to limit the disclosure of such information. Please read our Privacy Policy for more information.

CA0526.1

Privacy Policy

MiracleCord is committed to keeping the personal and health information you provide to us strictly confidential and to limit the disclosure of such information.

The Information

As a result of your enrollment as a Client of MiracleCord, you will be providing MiracleCord with various types of information. You will provide MiracleCord with personal identification information such as names, addresses, phone numbers and credit card numbers. You will also provide MiracleCord with a medical health history questionnaire that contains information about you. Included in “information” that is subject to this policy is any additional information you voluntarily provide to us.

You understand and agree that as a result of your use of this site and interest in MiracleCord that MiracleCord may communicate with you by means of any of email, text messaging, telephone or written communication. You have the right to opt out of such communications by using that means of communication you wish to stop at any time: (i) an email to MiracleCord at [email protected]; (ii) a text “STOP” in response to a MiracleCord text; (iii) a call to MiracleCord customer service at 1-888-743-2673; or (iv) by letter to MiracleCord at 875 N Michigan Ave, Ste 3100, Chicago, IL 60611.

MiracleCord’s Obligations of Confidentiality

With respect to the personal identification information you provide to us, MiracleCord will only disclose such information to its employees, agents, representatives and its service partners providing collection, testing and storage services related to the Specimens, and only where such individuals or entities have demonstrated a need to know for the purposes of completing the process of storing the Specimens as part of the program in which you have enrolled, and maintaining adequate records related to such storage. Without your consent, MiracleCord will not share or sell your information to any vendor, marketing or promotion firm or any other third party. One exception to this general commitment is that MiracleCord will comply with all applicable governmental orders or requirements as well as any judicial or other regulatory agency subpoenas. MiracleCord will notify you in the event it receives such order, requirement or subpoena.

With respect to the medical information you provide to MiracleCord, including your responses on the medical health history questionnaire and the results of any tests on the Specimens, MiracleCord will only disclose such information as required by applicable federal or state law. Additionally, MiracleCord may disclose such information to a third party for whom you have granted consent for such disclosure, including any medical professional providing health care services to you, your child or any third party. Any information related to the Specimens maintained by either MiracleCord or its service partners will be treated the same as medical information as described under this policy.